Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for…
![[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US](https://i0.wp.com/ml-eu.globenewswire.com/media/ZTQzNjcwMWUtZTZmZi00MTQ2LTk4YzEtMDM3YWJiOTVmYTcxLTEwMTQyODItMjAyNS0wNC0xNC1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US")
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules…